These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
16. Toxicity patterns associated with chemotherapy/immune checkpoint inhibitor combinations: a meta-analysis. Abdel-Rahman O Immunotherapy; 2019 Apr; 11(6):543-554. PubMed ID: 31135244 [No Abstract] [Full Text] [Related]
17. [Therapy monitoring and management of adverse events in PD-1/PD-L1 immune checkpoint inhibition]. Oppel-Heuchel H; Grimm MO Urologe A; 2016 May; 55(5):677-90. PubMed ID: 27146870 [TBL] [Abstract][Full Text] [Related]
18. Immunotherapy of advanced renal cell carcinoma: Current and future therapies. Gill D; Hahn AW; Sonpavde G; Agarwal N Hum Vaccin Immunother; 2016 Dec; 12(12):2997-3004. PubMed ID: 27494417 [TBL] [Abstract][Full Text] [Related]
19. How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors? Denis M; Duruisseaux M; Brevet M; Dumontet C Front Immunol; 2020; 11():492. PubMed ID: 32265935 [TBL] [Abstract][Full Text] [Related]
20. Incidence and Management of Immune-Related Adverse Events in Patients Undergoing Treatment with Immune Checkpoint Inhibitors. Kottschade LA Curr Oncol Rep; 2018 Mar; 20(3):24. PubMed ID: 29511902 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]